UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): September 7,
2010
ENTREMED,
INC.
(Exact
Name of Registrant as Specified in its Charter)
DELAWARE
(State
or other jurisdiction of
incorporation
or organization)
|
0-20713
(Commission
File Number)
|
58-1959440
(IRS
Employer Identification
No.)
|
9640
Medical Center Drive
Rockville,
Maryland
(Address
of principal executive offices)
20850
(Zip
Code)
(240)
864-2600
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
|
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR
230.425)
|
o
|
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
o
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
1.01. Entry Into a Material Definitive Agreement.
Offering
of Common Stock and Warrants to Purchase Common Stock
On
September 8, 2010, EntreMed, Inc., a Delaware corporation (“EntreMed” or “the
Company”), consummated the issuance and sale (the “Offering”)
of 1,886,622 shares (the “Shares”) of its common stock, par value
$0.01 per share (“Common Stock”) and warrants (“Warrants”) to purchase up to an
aggregate of 377,327 shares of Common Stock, to certain investors (collectively,
the “Investors”). The Offering was made pursuant to a securities
purchase agreement effective as of September 7, 2010 (the “Securities Purchase
Agreement”) between EntreMed and the Investors. The Shares and
Warrants were sold in units (the “Units”) consisting of one share of Common
Stock and a Warrant to purchase 0.20 shares of Common Stock. The
Shares and the Warrants are immediately separable and were issued
separately. The Warrants have a three year term from the date
of issuance, are exercisable at any time 181 days after the date of issuance and
will include provisions providing for adjustments to the number of shares
exercisable thereunder upon stock dividends, stock splits and similar
events.
In
accordance with the Securities Purchase Agreement, EntreMed issued and sold the
Units to the Investors for an aggregate purchase price of $5,094,000, or $2.70
per share, which price per share for the Shares represents the consolidated
closing bid price of the Company’s stock on September 7, 2010, as reported by
the Nasdaq Stock Market. The exercise price of the Warrants is
$2.825 per share.
A copy of
each of the form of Warrant and the form of Securities Purchase Agreement are
filed as Exhibits 4.1 and 10.1, respectively, to this Current Report on
Form 8-K, and are incorporated herein by reference. The
foregoing description of each of the Securities Purchase Agreement and Warrant
are a summary only and are subject to, and qualified in their entirety by, such
exhibits.
EntreMed
made the Offering pursuant to a shelf registration statement on Form S-3
(Registration No. 333-161100) previously filed and declared effective by the
Securities and Exchange Commission (the “Commission”) on October 9, 2009, and a
base prospectus dated as of the same date, as supplemented by a prospectus
supplement filed with the Commission on September 8, 2010.
In
connection with the financing and pursuant to the Securities Purchase Agreement,
the Investors were collectively offered the right to designate one director to
the Company’s Board of Directors, and the director nominee, if
selected, will be identified by SVT (as defined below) and submitted to EntreMed
for approval and election to EntreMed’s Board of
Directors. No director has been selected by SVT at this
time.
We have
agreed to pay to BroadOak Capital Partners, LLC (“BroadOak”), the advisor to the
Investors, an aggregate fee, on behalf of the Investors, equal to 5% of the
gross proceeds from the sale of the units in this offering, or
$254,700. The aggregate net proceeds from the Offering, after
deducting the fees due to BroadOak and estimated other offering expenses payable
by EntreMed, is expected to be approximately $4.7 million.
China
Rights Agreement
Concurrently with the Offering, on
September 7, 2010, the Company entered into a rights agreement with Selected
Value Therapeutics I, LLC, a Delaware limited liability company
(“SVT”) and an entity in which the purchasers have an interest, pursuant to
which SVT has an option to exercise, on behalf of the investors, certain
license, development and commercialization rights for the Company's lead product
candidate, ENMD-2076, in China. If the option is exercised, EntreMed
will be entitled to receive development milestone payments and royalties on
future product sales within the geographic market. The option
is exercisable at any time until December 31, 2011.
On
September 8, 2010, EntreMed issued a press release announcing the Offering
and the entry into the China Rights Agreement with SVT, the text of
which is filed as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated herein by reference. A copy of the legal opinion of
Arnold & Porter LLP relating to the securities issued in the Offering is
attached as Exhibit 5.1 to this Current Report on Form 8-K.
Item 8.01 Other
Information
.
As previously reported on a Current
Report on Form 8-K filed with the Commission on August 20, 2010, the Company
received a letter on August 17, 2010 from the Listing Qualifications Department
of the Nasdaq Stock Market indicating that the Company was
currently not in compliance with the minimum $35 million minimum market value of
listed securities requirement for continued listing on The
NASDAQ Capital Market under Rule 5550(b)(2). Pursuant to the terms of
the letter, the Company was provided with 180 days, or until February 14, 2011,
to regain compliance with the rule. During this period,
compliance will be regained if the market value of the Company's
listed securities closes at $35 million or more for a minimum of 10
consecutive business days, or if the Company satisfies one of the other
continued listing requirements under Rule 5550(b).
As of the
date of this Current Report on Form 8-K, as a result of the consummation of
the Offering described above, the Company believes that it has regained
compliance with the Nasdaq Stock Market stockholders’ equity continued listing
requirement under Rule 5550. The Company acknowledges that Nasdaq
will continue to monitor its ongoing compliance with the stockholders’ equity
requirement and, if at the time of the Company’s next periodic report it does
not evidence compliance, that it may be subject to delisting.
Item
9.01. Financial Statements and Exhibits.
|
Exhibit
Number
|
|
Description
|
|
|
|
|
|
4.1
|
|
Form
of Common Stock Purchase Warrant
|
|
|
|
|
|
5.1
|
|
Opinion
of Arnold & Porter LLP
|
|
|
|
|
|
10.1
|
|
Form
of Securities Purchase Agreement, by and among the Company and the
purchasers party thereto, dated September 7, 2010
|
|
|
|
|
|
23.1
|
|
Consent
of Arnold & Porter LLP (included as part of Exhibit
5.1)
|
|
|
|
|
|
99.1
|
|
Press
release dated September 8,
2010
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ENTREMED,
INC.
|
|
|
|
|
|
/s/ Cynthia W. Hu
|
|
|
Name:
|
Cynthia
W. Hu
|
|
|
Title:
|
Chief
Operating Officer, General Counsel &
Secretary
|
Date: September
10, 2010
Exhibit
Index
|
Exhibit
Number
|
|
Description
|
|
|
|
|
|
4.1
|
|
Form
of Common Stock Purchase Warrant
|
|
|
|
|
|
5.1
|
|
Opinion
of Arnold & Porter LLP
|
|
|
|
|
|
10.1
|
|
Form
of Securities Purchase Agreement, by and among the Company and the
purchasers party thereto, dated September 7, 2010
|
|
|
|
|
|
23.1
|
|
Consent
of Arnold & Porter LLP (included as part of Exhibit
5.1)
|
|
|
|
|
|
99.1
|
|
Press
release dated September 8,
2010
|
FORM
OF
COMMON
STOCK PURCHASE WARRANT
ENTREMED,
INC.
Warrant
Shares: [___]
|
Issue
Date: September 8, 2010
|
THIS
COMMON STOCK PURCHASE WARRANT (the “
Warrant
”) certifies
that, for value received,
[Name of
Investor]
(the “
Holder
”) is entitled,
upon the terms and subject to the limitations on exercise and the conditions
hereinafter set forth, at any time on or after 181 days following the Issue Date
(the “
Initial Exercise
Date
”) and on or prior to the close of business on the third anniversary
of the Initial Exercise Date (the “
Termination Date
”)
but not thereafter, to subscribe for and purchase from EntreMed, Inc., a
Delaware corporation (the “
Company
”), up to
[____] shares (the “
Warrant Shares
”) of
Common Stock.
Section
1
.
Definitions
. Capitalized
terms used and not otherwise defined herein shall have the meanings set forth in
that certain Securities Purchase Agreement (the “
Purchase Agreement
”),
dated September 7, 2010, among the Company and the purchasers signatory
thereto.
Section
2
.
Exercise
.
a)
Exercise of
Warrant
. Exercise of the purchase rights represented by this
Warrant may be made, in whole or in part, at any time or times on or after the
Initial Exercise Date and on or before the Termination Date by delivery to the
Company (or such other office or agency of the Company as it may designate by
notice in writing to the registered Holder at the address of the Holder
appearing on the books of the Company) of a duly executed facsimile copy of the
Notice of Exercise Form annexed hereto; and, within three (3) Trading Days of
the date said Notice of Exercise is delivered to the Company, the Company shall
have received payment of the aggregate Exercise Price of the shares thereby
purchased by wire transfer or cashier’s check drawn on a United States
bank. Notwithstanding anything herein to the contrary, the Holder
shall not be required to physically surrender this Warrant to the Company until
the Holder has purchased all of the Warrant Shares available hereunder and the
Warrant has been exercised in full, in which case, the Holder shall surrender
this Warrant to the Company for cancellation within three (3) Trading Days of
the date the final Notice of Exercise is delivered to the
Company. Partial exercises of this Warrant resulting in purchases of
a portion of the total number of Warrant Shares available hereunder shall have
the effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares
purchased. The Holder and the Company shall maintain records showing
the number of Warrant Shares purchased and the date of such
purchases. The Company shall deliver any objection to any Notice of
Exercise Form within 1 Business Day of receipt of such notice. In the
event of any dispute or discrepancy, the records of the Holder shall be
controlling and determinative in the absence of manifest error.
The Holder and any assignee, by
acceptance of this Warrant, acknowledge and agree that, by reason of the
provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder
at any given time may be less than the amount stated on the face
hereof.
b)
Exercise
Price
. The exercise price per share of the Common Stock under
this Warrant shall be $2.825, subject to adjustment hereunder (the “
Exercise
Price
”).
c)
Mechanics of
Exercise
.
i.
Delivery
of Certificates Upon Exercise
. Certificates for shares
purchased hereunder shall be transmitted by the Transfer Agent to the Holder by
crediting the account of the Holder’s prime broker with the Depository Trust
Company through its Deposit Withdrawal Agent Commission (“
DWAC
”) system if the
Company is then a participant in such system and there is an effective
Registration Statement permitting the issuance of the Warrant Shares to the
Holder, and otherwise by physical delivery to the address specified by the
Holder in the Notice of Exercise by the date that is three (3) Trading Days
after the latest of (A) the delivery to the Company of the Notice of Exercise
Form, (B) surrender of this Warrant (if required) and (C) payment of the
aggregate Exercise Price as set forth above (such date, the “
Warrant Share Delivery
Date
”). This Warrant shall be deemed to have been exercised on
the first date on which all of the foregoing have been delivered to the
Company. The Warrant Shares shall be deemed to have been issued, and
Holder or any other person so designated to be named therein shall be deemed to
have become a holder of record of such shares for all purposes, as of the date
the Warrant has been exercised, with payment to the Company of the Exercise
Price and all taxes required to be paid by the Holder, if any, pursuant to
Section 2(d)(vi) prior to the issuance of such shares, having been
paid.
ii.
Delivery of New Warrants
Upon Exercise
. If this Warrant shall have been exercised in
part, the Company shall, at the request of a Holder and upon surrender of this
Warrant certificate, at the time of delivery of the certificate or certificates
representing Warrant Shares, deliver to Holder a new Warrant evidencing the
rights of Holder to purchase the unpurchased Warrant Shares called for by this
Warrant, which new Warrant shall in all other respects be identical with this
Warrant.
iii.
No Fractional Shares or
Scrip
. No fractional shares or scrip representing fractional
shares shall be issued upon the exercise of this Warrant. As to any
fraction of a share which the Holder would otherwise be entitled to purchase
upon such exercise, the Company shall, at its election, either pay a cash
adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole
share.
iv.
Charges, Taxes and
Expenses
. Issuance of certificates for Warrant Shares shall be
made without charge to the Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of such certificate, all of which
taxes and expenses shall be paid by the Company, and such certificates shall be
issued in the name of the Holder or in such name or names as may be directed by
the Holder;
provided
,
however
, that in the
event certificates for Warrant Shares are to be issued in a name other than the
name of the Holder, this Warrant when surrendered for exercise shall be
accompanied by the Assignment Form attached hereto duly executed by the Holder
and the Company may require, as a condition thereto, the payment of a sum
sufficient to reimburse it for any transfer tax incidental thereto.
v.
Closing of
Books
. The Company will not close its stockholder books or
records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.
Section
3
.
Certain
Adjustments
.
a)
Stock Dividends and
Splits
. If the Company, at any time while this Warrant is outstanding:
(i) pays a stock dividend or otherwise makes a distribution or distributions on
shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not
include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger
number of shares, (iii) combines (including by way of reverse stock split)
outstanding shares of Common Stock into a smaller number of shares, or (iv)
issues by reclassification of shares of the Common Stock any shares of capital
stock of the Company, then in each case the Exercise Price shall be multiplied
by a fraction of which the numerator shall be the number of shares of Common
Stock (excluding treasury shares, if any) outstanding immediately before such
event and of which the denominator shall be the number of shares of Common Stock
outstanding immediately after such event, and the number of shares issuable upon
exercise of this Warrant shall be proportionately adjusted such that the
aggregate Exercise Price of this Warrant shall remain unchanged. Any
adjustment made pursuant to this Section 3(a) shall become effective immediately
after the record date for the determination of stockholders entitled to receive
such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or
re-classification.
b)
Calculations
. All
calculations under this Section 3 shall be made to the nearest cent or the
nearest 1/100th of a share, as the case may be. For purposes of this Section 3,
the number of shares of Common Stock deemed to be issued and outstanding as of a
given date shall be the sum of the number of shares of Common Stock (excluding
treasury shares, if any) issued and outstanding.
c)
Notice to
Holder
.
i.
Adjustment to
Exercise Price
. Whenever the Exercise Price is adjusted pursuant to this
Section 3, the Company shall promptly mail to the Holder a notice setting forth
the Exercise Price after such adjustment and setting forth a brief statement of
the facts requiring such adjustment.
ii.
Notice to Allow Exercise by
Holder
. If (A) the Company shall declare a dividend (or any other
distribution in whatever form) on the Common Stock, (B) the Company shall
declare a special nonrecurring cash dividend on or a redemption of the Common
Stock, (C) the Company shall authorize the granting to all holders of the Common
Stock rights or warrants to subscribe for or purchase any shares of capital
stock of any class or of any rights, (D) the approval of any stockholders of the
Company shall be required in connection with any reclassification of the Common
Stock, any consolidation or merger to which the Company is a party, any sale or
transfer of all or substantially all of the assets of the Company, or any
compulsory share exchange whereby the Common Stock is converted into other
securities, cash or property, or (E) the Company shall authorize the voluntary
or involuntary dissolution, liquidation or winding up of the affairs of the
Company, then, in each case, the Company shall cause to be mailed to the Holder
at its last address as it shall appear upon the Warrant Register of the Company,
concurrently with any notice provided to holders of the Company’s Common Stock
or filed with the Commission, a notice stating (x) the date on which a record is
to be taken for the purpose of such dividend, distribution, redemption, rights
or warrants, or if a record is not to be taken, the date as of which the holders
of the Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which
such reclassification, consolidation, merger, sale, transfer or share exchange
is expected to become effective or close, and the date as of which it is
expected that holders of the Common Stock of record shall be entitled to
exchange their shares of the Common Stock for securities, cash or other property
deliverable upon such reclassification, consolidation, merger, sale, transfer or
share exchange; provided that the failure to mail such notice or any defect
therein or in the mailing thereof shall not affect the validity of the corporate
action required to be specified in such notice. The Holder shall remain entitled
to exercise this Warrant during the period commencing on the date of such notice
to the effective date of the event triggering such notice except as may
otherwise be expressly set forth herein.
Section
4
.
Transfer of
Warrant
.
a)
Transferability
. This
Warrant and all rights hereunder are transferable, in whole or in part, upon
surrender of this Warrant at the principal office of the Company or its
designated agent, together with (i) a written assignment of this Warrant
substantially in the form attached hereto duly executed by the Holder or its
agent or attorney and funds sufficient to pay any transfer taxes payable upon
the making of such transfer and (ii) any other documents or certificates
reasonably requested by the Company to effect such transfer. Upon
such surrender and, if required, such payment, the Company shall execute and
deliver a new Warrant or Warrants in the name of the assignee or assignees, as
applicable, and in the denomination or denominations specified in such
instrument of assignment, and shall issue to the assignor a new Warrant
evidencing the portion of this Warrant not so assigned, and this Warrant shall
promptly be cancelled. The Warrant, if properly assigned in
accordance herewith, may be exercised by a new holder for the purchase of
Warrant Shares without having a new Warrant issued.
b)
New Warrants
. This
Warrant may be divided or combined with other Warrants upon presentation hereof
at the aforesaid office of the Company, together with a written notice
specifying the names and denominations in which new Warrants are to be issued,
signed by the Holder or its agent or attorney. Subject to compliance
with Section 4(a), as to any transfer which may be involved in such division or
combination, the Company shall execute and deliver a new Warrant or Warrants in
exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated
the initial issuance date set forth on the first page of this Warrant and shall
be identical with this Warrant except as to the number of Warrant Shares
issuable pursuant thereto.
c)
Warrant Register
. The
Company shall register this Warrant, upon records to be maintained by the
Company for that purpose (the “
Warrant Register
”),
in the name of the record Holder hereof from time to time. The
Company may deem and treat the registered Holder of this Warrant as the absolute
owner hereof for the purpose of any exercise hereof or any distribution to the
Holder, and for all other purposes, absent actual notice to the
contrary.
Section
5
.
Miscellaneous
.
a)
No Rights as Stockholder
Until Exercise
. This Warrant does not entitle the Holder to
any voting rights, dividends or other rights as a stockholder of the Company
prior to the exercise hereof as set forth in Section 2.
b)
Loss, Theft, Destruction or
Mutilation of Warrant
. The Company covenants that upon receipt by the
Company of evidence reasonably satisfactory to it of the loss, theft,
destruction or mutilation of this Warrant or any stock certificate relating to
the Warrant Shares, and in case of loss, theft or destruction, of indemnity or
security reasonably satisfactory to it (which, in the case of the Warrant, shall
not include the posting of any bond), and upon surrender and cancellation of
such Warrant or stock certificate, if mutilated, the Company will make and
deliver a new Warrant or stock certificate of like tenor and dated as of such
cancellation, in lieu of such Warrant or stock certificate.
c)
Saturdays, Sundays,
Holidays, etc
. If the last or appointed day for the taking of
any action or the expiration of any right required or granted herein shall not
be a Business Day, then, such action may be taken or such right may be exercised
on the next succeeding Business Day.
d)
Authorized Shares;
Noncircumvention
.
The
Company covenants that, during the period the Warrant is outstanding, it will
reserve from its authorized and unissued Common Stock a sufficient number of
shares to provide for the issuance of the Warrant Shares upon the exercise of
any purchase rights under this Warrant. The Company further covenants
that its issuance of this Warrant shall constitute full authority to its
officers who are charged with the duty of executing stock certificates to
execute and issue the necessary certificates for the Warrant Shares upon the
exercise of the purchase rights under this Warrant. The Company will
take all such reasonable action as may be necessary to assure that such Warrant
Shares may be issued as provided herein without violation of any applicable law
or regulation, or of any requirements of the Trading Market upon which the
Common Stock may be listed. The Company covenants that all Warrant
Shares which may be issued upon the exercise of the purchase rights represented
by this Warrant will, upon exercise of the purchase rights represented by this
Warrant and payment for such Warrant Shares in accordance herewith, be duly
authorized, validly issued, fully paid and nonassessable.
Except
and to the extent as waived or consented to by the Holder, the Company shall not
by any action, including, without limitation, amending its certificate of
incorporation or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action,
avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all
such terms and in the taking of all such actions as may be necessary or
appropriate to protect the rights of Holder as set forth in this Warrant against
impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the
amount payable therefor upon such exercise immediately prior to such increase in
par value, (ii) take all such action as may be necessary or appropriate in order
that the Company may validly and legally issue fully paid and nonassessable
Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents
from any public regulatory body having jurisdiction thereof, as may be,
necessary to enable the Company to perform its obligations under this
Warrant.
Before
taking any action which would result in an adjustment in the number of Warrant
Shares for which this Warrant is exercisable or in the Exercise Price, the
Company shall obtain all such authorizations or exemptions thereof, or consents
thereto, as may be necessary from any public regulatory body or bodies having
jurisdiction thereof.
e)
Jurisdiction
. All
questions concerning the construction, validity, enforcement and interpretation
of this Warrant shall be determined in accordance with the provisions of the
Purchase Agreement.
f)
Nonwaiver and
Expenses
. No course of dealing or any delay or failure to
exercise any right hereunder on the part of Holder shall operate as a waiver of
such right or otherwise prejudice Holder’s rights, powers or
remedies.
g)
Notices
. Any
notice, request or other document required or permitted to be given or delivered
to the Holder by the Company shall be delivered in accordance with the notice
provisions of the Purchase Agreement.
h)
Remedies
. The
Holder, in addition to being entitled to exercise all rights granted by law,
including recovery of damages, will be entitled to specific performance of its
rights under this Warrant. The Company agrees that monetary damages
would not be adequate compensation for any loss incurred by reason of a breach
by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law
would be adequate.
i)
Successors and
Assigns
. Subject to applicable securities laws, this Warrant
and the rights and obligations evidenced hereby shall inure to the benefit of
and be binding upon the successors and permitted assigns of the Company and the
successors and permitted assigns of Holder. The provisions of this
Warrant are intended to be for the benefit of any Holder from time to time of
this Warrant and shall be enforceable by the Holder or holder of Warrant
Shares.
j)
Amendment
. This
Warrant may be modified or amended or the provisions hereof waived with the
written consent of the Company and the Holder.
k)
Severability
. Wherever
possible, each provision of this Warrant shall be interpreted in such manner as
to be effective and valid under applicable law, but if any provision of this
Warrant shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such prohibition or invalidity, without
invalidating the remainder of such provisions or the remaining provisions of
this Warrant.
l)
Headings
. The
headings used in this Warrant are for the convenience of reference only and
shall not, for any purpose, be deemed a part of this Warrant.
********************
(Signature
Pages Follow)
IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its
officer thereunto duly authorized as of the date first above
indicated.
|
ENTREMED,
INC.
|
|
|
|
|
By:
|
|
|
|
Name: Michael
M. Tarnow
|
|
|
Title:
Executive Chairman
|
NOTICE
OF EXERCISE
TO: ENTREMED,
INC.
(1)
The undersigned
hereby elects to purchase ________ Warrant Shares of the Company pursuant to the
terms of the attached Warrant (only if exercised in full), and tenders herewith
payment of the exercise price in full, together with all applicable transfer
taxes, if any. Payment shall take the form of in lawful
money of the United States, by wire transfer of immediately available funds or
by check.
(2)
Please issue a
certificate or certificates representing said Warrant Shares in the name of the
undersigned or in such other name as is specified below:
________________________________________
The
Warrant Shares shall be delivered to the following DWAC Account Number or by
physical delivery of a certificate to:
________________________________________
________________________________________
________________________________________
[SIGNATURE
OF HOLDER]
Name of
Investing Entity:
___________________________________________________________________________
Signature of Authorized Signatory of
Investing Entity
:
_____________________________________________________
Name of
Authorized Signatory:
_______________________________________________________________________
Title of
Authorized Signatory:
________________________________________________________________________
Date:
__________________________________________________________________________________________
ASSIGNMENT
FORM
(To
assign the foregoing warrant, execute
this form
and supply required information.
Do not
use this form to exercise the warrant.)
FOR VALUE
RECEIVED, [____] all of or [_______] shares of the foregoing Warrant and all
rights evidenced thereby are hereby assigned to
________________________________________________________
whose
address is
|
|
______________________________________________________________
.
|
|
|
____________________________________________________________________
|
|
Dated: ______________,
_______
|
|
|
|
Holder’s
Signature: _______________________________
|
|
|
|
Holder’s
Address:
_______________________________
|
|
|
|
_______________________________
|
Signature
Guaranteed:
___________________________________________
NOTE: The
signature to this Assignment Form must correspond with the name as it appears on
the face of the Warrant, without alteration or enlargement or any change
whatsoever, and must be guaranteed by a bank or trust
company. Officers of corporations and those acting in a fiduciary or
other representative capacity should file proper evidence of authority to assign
the foregoing Warrant.
Exhibit
5.1
[Arnold
& Porter LLP Letterhead]
September
8, 2010
EntreMed,
Inc.
9640
Medical Center Drive
Rockville,
MD 20850
Ladies
and Gentlemen:
We have
acted as special counsel to EntreMed, Inc., a Delaware corporation (the “
Company
”), in
connection with the offering by the Company of 1,886,662 shares of the Company’s
common stock, par value $0.01 per share (the “
Shares
”) and 377,327
warrants to purchase common stock of the Company (each, a “
Warrant
” and
together, the “
Warrants
”, and
together with the Shares, the “
Securities
”),
pursuant to (i) the Registration Statement on Form S-3 (file
no. 333-161100), which was declared effective by the Securities and
Exchange Commission (the “
Commission
”) on
October 9, 2009 (the “
Registration
Statement
”) under the Securities Act of 1933, as amended (the “
Securities Act
”), the
base Prospectus dated October 9, 2009 and the related Prospectus Supplement to
be filed with the Commission (together with the base Prospectus, the “
Prospectus
Supplement
”); (ii) the securities purchase agreement dated as of
September 7, 2010 (the “
Securities Purchase
Agreement
”) between the Company and the purchasers (each, a “
Purchaser
” and
collectively, the “
Purchasers”
) to be
filed by the Company as Exhibit 10.1 to its Current Report on Form 8-K
on or about September 10, 2010 (the “
Form 8-K
”); and
(iii) the form of Warrant to be filed by the Company as Exhibit 4.1 to the Form
8-K. This opinion letter is furnished to you at your request to
enable you to fulfill the requirements of Item 601(b)(5) of
Regulation S-K, 17 C.F.R. § 229.601(b)(5), in
connection with the Registration Statement.
For
purposes of this opinion letter, we have examined originals or copies, certified
or otherwise identified to our satisfaction, of such agreements, corporate
records, instruments and other documents as we have deemed necessary or
appropriate for the purpose of rendering the opinions hereinafter
expressed. In our examination of the aforesaid documents, we have
assumed the genuineness of all signatures, the legal capacity of all natural
persons, the accuracy and completeness of all documents submitted to us, the
authenticity of all original documents, and the conformity to authentic original
documents of all documents submitted to us as copies (including
telecopies). As to all matters of fact, we have relied on the
representations and statements of fact made in the documents so reviewed, and we
have not independently established the facts so relied on. This
opinion letter is given, and all statements herein are made, in the context of
the foregoing.
This
opinion letter is based as to matters of law solely on the Delaware General
Corporation Law, as amended. We express no opinion herein as to any
other laws, statutes, ordinances, rules or regulations. As used
herein, the term “Delaware General Corporation Law, as amended” includes the
statutory provisions contained therein, all applicable provisions of the
Delaware Constitution and reported judicial decisions interpreting these
laws.
Based
upon, subject to and limited by the foregoing and the further assumptions,
qualifications and limitations set forth herein, we are of the opinion that,
when the Securities are issued and delivered to the Purchasers upon the terms
and subject to the conditions set forth in, and in the manner contemplated by,
the Securities Purchase Agreement and the Prospectus Supplement and against
receipt by the Company of the consideration therefor as provided therein, (i)
the Shares will be validly issued, fully paid and nonassessable and the Warrants
shall be validly issued, and (ii) upon the exercise and payment of the
consideration as set forth therein, the shares of common stock issuable upon
exercise of the Warrants will be validly issued, fully paid and
nonassessable.
The
opinion expressed herein is based upon the assumption that there will be no
material changes in the documents examined and matters investigated and that at
the time of issuance of the Shares there will be authorized but unissued shares
of common stock of the Company available in amounts sufficient for such
issuance.
This
opinion letter has been prepared for use in connection with the Registration
Statement. This opinion speaks as of today’s date and is limited to
present statutes, regulations and judicial interpretations. In
rendering this opinion, we assume no obligation to revise or supplement this
opinion should present laws, regulations or judicial interpretations be changed
by legislative or regulatory action, judicial decision or
otherwise. This opinion is limited to the matters expressly set forth
herein, and no other opinion should be inferred beyond such
matters.
We hereby
consent to the filing of this opinion letter as Exhibit 5.1 to the Form
8-K, and to the reference to this firm under the caption “Legal Matters” in the
Prospectus Supplement. By giving such consent we do not thereby admit
that we are within the category of persons whose consent is required under
Section 7 of the Securities Act, or the rules and regulations of the
Commission thereunder.
This
opinion is rendered solely to you in connection with the above matter. This
opinion may not be relied upon by you for any other purpose or relied upon by or
furnished to any other person without our prior written consent.
Very
truly yours,
/s/
Arnold & Porter LLP
SECURITIES
PURCHASE AGREEMENT
This
Securities Purchase Agreement (this “
Agreement
”) is dated
as of September 7, 2010, between EntreMed, Inc., a Delaware corporation (the
“
Company
”), and
each purchaser identified on the signature pages hereto (each, including its
successors and assigns, a “
Purchaser
” and
collectively the “
Purchasers
”).
WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to
an effective registration statement under the Securities Act of 1933, as amended
(the “
Securities
Act
”), the Company desires to issue and sell to each Purchaser, and each
Purchaser, severally and not jointly, desires to purchase from the Company,
securities of the Company as more fully described in this
Agreement.
NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement,
and for other good and valuable consideration the receipt and adequacy of which
are hereby acknowledged, the Company and each Purchaser agree as
follows:
ARTICLE
I.
DEFINITIONS
1.1
Definitions
. In addition to the terms defined elsewhere in
this Agreement, for all purposes of this Agreement, the following terms have the
meanings set forth in this Section 1.1:
“
Business Day
” means
any day except any Saturday, any Sunday, any day which is a federal legal
holiday in the United States or any day on which banking institutions in the
State of New York are authorized or required by law or other governmental action
to close.
“
Closing
” means the
closing of the purchase and sale of the Securities pursuant to Section
2.1.
“
Closing Date
” means
the Trading Day on which all of the Transaction Documents have been executed and
delivered by the applicable parties thereto, and all conditions precedent to (i)
the Purchasers’ obligations to pay the Subscription Amount and (ii) the
Company’s obligations to deliver the Securities, in each case, have been
satisfied or waived, but in no event later than the third Trading Day following
the date hereof.
“
Commission
” means the
United States Securities and Exchange Commission.
“
Common Stock
” means
the common stock of the Company, par value $0.01 per share, and any other class
of securities into which such securities may hereafter be reclassified or
changed.
“
Per Share Purchase
Price
” equals $2.70, subject to adjustment for reverse and forward stock
splits, stock dividends, stock combinations and other similar transactions of
the Common Stock that occur after the date of this Agreement.
“
Person
” means an
individual or corporation, partnership, trust, incorporated or unincorporated
association, joint venture, limited liability company, joint stock company,
government (or an agency or subdivision thereof) or other entity of any
kind.
“
Prospectus
” means the
final prospectus filed for the Registration Statement.
“
Prospectus
Supplement
” means the supplement to the Prospectus complying with Rule
424(b) of the Securities Act that is filed with the Commission and delivered by
the Company to each Purchaser at the Closing.
“
Registration
Statement
” means the effective registration statement with Commission
file No. 333-161100 which registers the sale of the Shares, the Warrants and the
Warrant Shares by the Purchasers.
“
Rule 424
” means Rule
424 promulgated by the Commission pursuant to the Securities Act, as such Rule
may be amended or interpreted from time to time, or any similar rule or
regulation hereafter adopted by the Commission having substantially the same
purpose and effect as such Rule.
“
Securities
” means the
Shares, the Warrants and the Warrant Shares.
“
Shares
” means the
shares of Common Stock issued or issuable to each Purchaser pursuant to this
Agreement.
“
Subscription Amount
”
means, as to each Purchaser, the aggregate amount to be paid for Shares and
Warrants purchased hereunder as specified below such Purchaser’s name on the
signature page of this Agreement and next to the heading “Subscription Amount,”
in United States dollars and in immediately available funds.
“
Trading Day
” means a
day on which the principal Trading Market is open for trading.
“
Trading Market
” means
any of the following markets or exchanges on which the Common Stock is listed or
quoted for trading on the date in question: the Nasdaq Capital Market, the
Nasdaq Global Market, the Nasdaq Global Select Market, the NYSE AMEX or the New
York Stock Exchange (or any successors to any of the foregoing).
“
Transaction
Documents
” means this Agreement, the Warrants and any other documents or
agreements executed in connection with the transactions contemplated
hereunder.
“
Transfer Agent
” means
American Stock Transfer & Trust Company, the current transfer agent of the
Company, and any successor transfer agent of the Company.
“
Warrants
” means,
collectively, the Common Stock purchase warrants delivered to the Purchasers at
the Closing in accordance with Section 2.2(a) hereof, which Warrants shall be
exercisable 181 days from the date hereof and have a term of exercise equal to
three years from the date of exercise, in the form of
Exhibit A
attached
hereto.
“
Warrant Shares
” means
the shares of Common Stock issuable upon exercise of the Warrants.
ARTICLE
II.
PURCHASE
AND SALE
2.1
Closing
. On
the Closing Date, upon the terms and subject to the conditions set forth herein,
substantially concurrent with the execution and delivery of this Agreement by
the parties hereto, the Company agrees to sell, and the Purchasers, severally
and not jointly, agree to purchase, up to an aggregate of $5,100,000 of Shares
and Warrants. The Shares and Warrants will be sold together as units,
each unit consisting of one shares of Common Stock and a Warrant to purchase
0.20 shares of Common Stock. Each Purchaser shall deliver to the
Company, via wire transfer of immediately available funds, the amount equal to
such Purchaser’s Subscription Amount as set forth on the signature page hereto
executed by such Purchaser and the Company shall deliver to each Purchaser its
respective Shares and a Warrant as determined pursuant to Section 2.2(a), and
the Company and each Purchaser shall deliver the other items set forth in
Section 2.2 deliverable at the Closing. Upon satisfaction of the
covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall
occur at 10:00 a.m. at the offices of Arnold & Porter LLP, 555 Twelfth
Street, N.W., Washington, D.C. 20005 or such other location as the parties shall
mutually agree.
2.2
Deliveries
.
(a)
On
or prior to the Closing Date, the Company shall deliver or cause to be delivered
to each Purchaser the following:
(i)
this
Agreement duly executed by the Company;
(ii)
a
Warrant registered in the name of such Purchaser to purchase the number of
shares of Common Stock set forth in such Warrant, with an exercise price equal
to $2.825 subject to adjustment therein (such Warrant certificate may be
delivered within three Trading Days of the Closing Date); and
(iii)
the
Prospectus and Prospectus Supplement (which may be delivered in accordance with
Rule 172 under the Securities Act).
(b)
On
or prior to the Closing Date, each Purchaser shall deliver or cause to be
delivered to the Company the following:
(i)
this
Agreement duly executed by such Purchaser; and
(ii)
such Purchaser’s Subscription Amount by wire transfer to the account as
specified in writing by the Company or by delivery of immediately available
funds.
2.3
Closing
Conditions
.
(a) The
obligations of the Company hereunder in connection with the Closing are subject
to the following conditions being met:
(i)
the
accuracy in all material respects on the Closing Date of the representations and
warranties of the Purchasers contained herein (unless as of a specific date
therein);
(ii)
all
obligations, covenants and agreements of each Purchaser required to be performed
at or prior to the Closing Date shall have been performed; and
(iii)
the
delivery by each Purchaser of the items set forth in Section 2.2(b) of this
Agreement.
(b)
The
respective obligations of the Purchasers hereunder in connection with the
Closing are subject to the following conditions being met:
(i)
the
accuracy in all material respects when made and on the Closing Date of the
representations and warranties of the Company contained herein (unless as of a
specific date therein);
(ii)
all
obligations, covenants and agreements of the Company required to be performed at
or prior to the Closing Date shall have been performed; and
(iii)
the
delivery by the Company of the items set forth in Section 2.2(a) of this
Agreement.
ARTICLE
III.
REPRESENTATIONS,
WARRANTIES AND COVENANTS
3.1
Representations and
Warranties of the Company
. The Company hereby represents,
warrants and covenants to each Purchaser as follows:
(a)
The
issuance and sale of each of the Shares and the Warrants have been duly
authorized by the Company, and the Shares, when issued and paid for in
accordance with this Agreement, will be duly and validly issued, fully paid and
nonassessable. The Warrant Shares have been duly authorized and
reserved for issuance pursuant to the terms of the Warrants, and the Warrant
Shares, when issued by the Company upon valid exercise of the Warrants and
payment of the exercise price, will be duly and validly issued, fully paid and
nonassessable.
(b)
Each
of this Agreement and the Warrants constitutes a valid and binding obligation of
the Company enforceable against the Company in accordance with its
terms,.
(c)
The
Company will use its commercially reasonable efforts to maintain the
effectiveness of the Registration Statement in accordance with the rules and
regulations promulgated by the Commission.
(d)
As
of the Closing Date, the Company shall have duly authorized and reserved for
issuance a number of shares of Common Stock which equals the number of
Warrants. The Company shall, so long as any of the Warrants are
outstanding, take all action necessary to reserve and keep available out of its
authorized and unissued capital stock, solely for the purpose of
effecting the exercise of the Warrants, all of the number of Warrant
Shares.
(e)
Within
one Business Day of the Closing, the Company shall deliver irrevocable
instructions to the Transfer Agent instructing the Transfer Agent to deliver via
the Depository Trust Company Deposit Withdrawal Agent Commission System (“
DWAC
”), of if
requested, by physical stock certificate as soon as practicable, that number of
Shares equal to such Purchaser’s Subscription Amount divided by the Per Share
Purchase Price, registered in the name of such Purchaser.
3.2
Representations and
Warranties of the Purchasers
. Each Purchaser, for itself and
for no other Purchaser, hereby represents and warrants as follows:
(a)
Such
Purchaser has received the Company’s base prospectus relating to the Securities
and the prospectus supplement dated the date hereof. Such Purchaser
acknowledges that such Purchaser has received certain additional information
regarding the Offering, including pricing information (the “
Offering
Information
”). Such Offering Information may be provided to
the Purchaser by any means permitted under the Securities Act, including through
a prospectus supplement, a free writing prospectus or oral
communications.
(b)
Such
Purchaser has full right, power, authority and capacity to enter into this
Agreement and to consummate the transactions contemplated hereby and has taken
all necessary action to authorize the execution, delivery and performance of
this Agreement, and this Agreement constitutes a valid and binding obligation of
such Purchaser enforceable against such Purchaser in accordance with its
terms.
(c)
Such
Purchaser understands that nothing in the Registration Statement, the base
prospectus, the Offering Information and any amendments or supplements thereto,
this Agreement or any other materials presented to such Purchaser in connection
with the purchase and sale of the Securities constitutes legal, tax or
investment advice. Such Purchaser has consulted such legal, tax and
investment advisors as it, in its sole discretion, has deemed necessary or
appropriate in connection with its purchase of the Securities.
ARTICLE
IV.
OTHER
AGREEMENTS OF THE PARTIES
4.1
Board of
Directors
. The Company shall use its best efforts to
take all action necessary in accordance with the Delaware General Corporation
Law, applicable Trading Market rules, its Certificate of Incorporation and its
Amended and Restated Bylaws, and shall use its best efforts to take all other
actions necessary in connection with the rights granted under this Section 4.1,
to ensure that the Purchasers shall have the right to designate one individual
to serve as a member of the Company’s Board of Directors (the “
Purchaser
Designee
”). The Purchaser Designee will be named by Selected
Value Therapeutics GP, LLC and be acceptable to the Company. In lieu
of a board seat, Selected Value Therapeutics GP, LLC may instead elect, at its
option, to designate an observer to the Board (the “
Purchaser
Observer
”). Such Purchaser Observer may attend, in person, as
an observer, all meetings held in person and participate in telephonic meetings
of the Board of Directors of the Company, provided that such Purchaser Observer
shall not be entitled to vote on any matter brought to a vote at any such
meeting. The Company reserves the right to withhold any information
and to exclude such Purchaser Observer from any meeting, or any portion thereof,
as is reasonably determined by the Chairman of the Board or a majority of the
members of the Board of Directors or any committee thereof (in the case of
committee meetings) to be necessary for purposes of confidentiality, competitive
factors, attorney-client privilege or other reasonable purposes (at the sole
discretion of the Chairman of the Board or a majority of the members of the
Board of Directors or a majority of the members of any committee, with respect
to a meeting of such committee, as applicable).
4.2
Warrant
Shares
. If at any time following the date hereof the
Registration Statement (or any subsequent registration statement registering the
exercise of the Warrant Shares) is not effective or is not otherwise available
for the sale or resale of the Warrant Shares, the Company shall immediately
notify the holders of the Warrants in writing that such registration statement
is not then effective and thereafter shall promptly notify such holders when the
registration statement is again effective. The Company shall use
commercially reasonable efforts to keep a registration statement (including the
Registration Statement) registering the issuance of the Warrant Shares effective
during the term of the Warrants.
4.3
Use of
Proceeds
. The Company shall use the net proceeds from the sale
of the Securities hereunder for working capital purposes and as set forth in the
Prospectus Supplement.
4.4
L
isting of Common
Stock
. The Company hereby agrees to use best efforts to maintain the
listing or quotation of the Common Stock on the Trading Market on which it is
currently listed, and concurrently with the Closing, the Company shall apply to
list or quote all of the Shares and Warrant Shares on such Trading Market and
promptly secure the listing of all of the Shares and Warrant Shares on such
Trading Market. The Company further agrees, if the Company applies to have the
Common Stock traded on any other Trading Market, it will then include in such
application all of the Shares and Warrant Shares, and will take such other
action as is necessary to cause all of the Shares and Warrant Shares to be
listed or quoted on such other Trading Market as promptly as
possible. The Company will then take all action reasonably necessary
to continue the listing and trading of its Common Stock on a Trading Market and
will comply in all respects with the Company’s reporting, filing and other
obligations under the bylaws or rules of the Trading Market.
ARTICLE
V.
MISCELLANEOUS
5.1
Fees and
Expenses
. Each party shall pay the fees and expenses of its
advisers, counsel, accountants and other experts, if any, and all other expenses
incurred by such party incident to the negotiation, preparation, execution,
delivery and performance of this Agreement; provided, however, that the Company
shall reimburse Selected Value Therapeutics GP, LLC for its reasonable expenses
up to a maximum of $3,000, and agrees to reimburse the Purchasers for their
financial advisory expenses equal to 5% of the aggregate purchase price of the
Securities purchased pursuant to this Agreement. The Company shall
pay all Transfer Agent fees, stamp taxes and other taxes and duties levied in
connection with the delivery of any Securities to the Purchasers.
5.2
Entire
Agreement
. The Transaction Documents, together with the
exhibits and schedules thereto, the Prospectus and the Prospectus Supplement,
contain the entire understanding of the parties with respect to the subject
matter hereof and supersede all prior agreements and understandings, oral or
written, with respect to such matters, which the parties acknowledge have been
merged into such documents, exhibits and schedules.
5.3
Notices
. Any
and all notices or other communications or deliveries required or permitted to
be provided hereunder shall be in writing and shall be deemed given and
effective on the earliest of: (a) the date of transmission, if such notice or
communication is delivered via facsimile at the facsimile number set forth on
the signature pages attached hereto prior to 5:30 p.m. (New York City time) on a
Trading Day, (b) the next Trading Day after the date of transmission, if such
notice or communication is delivered via facsimile at the facsimile number set
forth on the signature pages attached hereto on a day that is not a Trading Day
or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second
(2
nd
)
Trading Day following the date of mailing, if sent by U.S. nationally recognized
overnight courier service or (d) upon actual receipt by the party to whom such
notice is required to be given. The address for such notices and
communications shall be as set forth on the signature pages attached
hereto.
5.4
Amendments;
Waivers
. No provision of this Agreement may be waived,
modified, supplemented or amended except in a written instrument signed, in the
case of an amendment, by the Company and the Purchasers holding at least 67% in
interest of the Shares then outstanding or, in the case of a waiver, by the
party against whom enforcement of any such waived provision is
sought. No waiver of any default with respect to any provision,
condition or requirement of this Agreement shall be deemed to be a continuing
waiver in the future or a waiver of any subsequent default or a waiver of any
other provision, condition or requirement hereof, nor shall any delay or
omission of any party to exercise any right hereunder in any manner impair the
exercise of any such right.
5.5
Headings
. The
headings herein are for convenience only, do not constitute a part of this
Agreement and shall not be deemed to limit or affect any of the provisions
hereof.
5.6
Successors and
Assigns
. This Agreement shall be binding upon and inure to the
benefit of the parties and their successors and permitted
assigns. The Company may not assign this Agreement or any rights or
obligations hereunder without the prior written consent of each Purchaser (other
than by merger). Any Purchaser may assign any or all of its rights
under this Agreement to any Person to whom such Purchaser assigns or transfers
any Securities, provided that such transferee agrees in writing to be bound,
with respect to the transferred Securities, by the provisions of the Transaction
Documents that apply to the “Purchasers.”
5.7
No Third-Party
Beneficiaries
. This Agreement is intended for the benefit of
the parties hereto and their respective successors and permitted assigns and is
not for the benefit of, nor may any provision hereof be enforced by, any other
Person.
5.8
Governing
Law
. All questions concerning the construction, validity,
enforcement and interpretation of the Transaction Documents shall be governed by
and construed and enforced in accordance with the internal laws of the State of
New York, without regard to the principles of conflicts of law
thereof.
5.9
Survival
. The
representations and warranties contained herein shall survive the Closing and
the delivery of the Securities.
5.10
Execution
. This
Agreement may be executed in two or more counterparts, all of which when taken
together shall be considered one and the same agreement and shall become
effective when counterparts have been signed by each party and delivered to the
other party, it being understood that both parties need not sign the same
counterpart. In the event that any signature is delivered by
facsimile transmission or by e-mail delivery of a “.pdf” format data file, such
signature shall create a valid and binding obligation of the party executing (or
on whose behalf such signature is executed) with the same force and effect as if
such facsimile or “.pdf” signature page were an original thereof.
5.11
Severability
. If
any term, provision, covenant or restriction of this Agreement is held by a
court of competent jurisdiction to be invalid, illegal, void or unenforceable,
the remainder of the terms, provisions, covenants and restrictions set forth
herein shall remain in full force and effect and shall in no way be affected,
impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same
or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the
intention of the parties that they would have executed the remaining terms,
provisions, covenants and restrictions without including any of such that may be
hereafter declared invalid, illegal, void or unenforceable.
5.12
Replacement of
Securities
. If any certificate or instrument evidencing any
Securities is mutilated, lost, stolen or destroyed, the Company shall issue or
cause to be issued in exchange and substitution for and upon cancellation
thereof (in the case of mutilation), or in lieu of and substitution therefor, a
new certificate or instrument, but only upon receipt of evidence reasonably
satisfactory to the Company of such loss, theft or destruction. The
applicant for a new certificate or instrument under such circumstances shall
also pay any reasonable third-party costs (including customary indemnity)
associated with the issuance of such replacement Securities.
5.13
Independent Nature of
Purchasers’ Obligations and Rights
. The obligations of each
Purchaser under any Transaction Document are several and not joint with the
obligations of any other Purchaser, and no Purchaser shall be responsible in any
way for the performance or non-performance of the obligations of any other
Purchaser under any Transaction Document. Nothing contained herein or
in any other Transaction Document, and no action taken by any Purchaser pursuant
thereto, shall be deemed to constitute the Purchasers as a partnership, an
association, a joint venture or any other kind of entity, or create a
presumption that the Purchasers are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by the
Transaction Documents. Each Purchaser shall be entitled to
independently protect and enforce its rights including, without limitation, the
rights arising out of this Agreement or out of the other Transaction Documents,
and it shall not be necessary for any other Purchaser to be joined as an
additional party in any proceeding for such purpose. The Company has
elected to provide all Purchasers with the same terms and Transaction Documents
for the convenience of the Company and not because it was required or requested
to do so by any of the Purchasers.
5.14
Saturdays, Sundays,
Holidays, etc.
If the last or appointed day
for the taking of any action or the expiration of any right required or granted
herein shall not be a Business Day, then such action may be taken or such right
may be exercised on the next succeeding Business Day.
5.15
Construction
. The
parties agree that each of them and/or their respective counsel has reviewed and
had an opportunity to revise the Transaction Documents and, therefore, the
normal rule of construction to the effect that any ambiguities are to be
resolved against the drafting party shall not be employed in the interpretation
of the Transaction Documents or any amendments hereto. In addition, each and
every reference to share prices and shares of Common Stock in any Transaction
Document shall be subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the Common
Stock that occur after the date of this Agreement.
5.16
WAIVER OF JURY
TRIAL
.
IN ANY ACTION, SUIT, OR
PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE
PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY
APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY
WAIVES FOREVER TRIAL BY JURY.
IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase
Agreement to be duly executed by their respective authorized signatories as of
the date first indicated above.
ENTREMED,
INC.
|
|
By:_____________________________
|
|
Name: Michael M. Tarnow
|
|
Title: Executive Chairman
|
|
|
|
Address
for notice:
|
|
|
|
9640
Medical Center Drive
|
|
Rockville,
Maryland 20850
|
|
Attention: General
Counsel & Secretary
|
|
Facsimile: 240.864.2601
|
|
|
|
With
a copy to (which shall not constitute notice):
|
|
Richard
E. Baltz
Arnold
& Porter LLP
555
12
th
St., N.W.
Washington,
D.C. 20004
Facsimile: 202.942.5999
|
|
[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK
SIGNATURE
PAGE FOR PURCHASER FOLLOWS]
[PURCHASER
SIGNATURE PAGES TO SECURITIES PURCHASE AGREEMENT]
IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement
to be duly executed by their respective authorized signatories as of the date
first indicated above.
Name of
Purchaser: ________________________________________________________
Signature
of Authorized Signatory of Purchaser:
_________________________________
Name of
Authorized Signatory:
_______________________________________________
Title of
Authorized Signatory:
________________________________________________
Facsimile
Number of Authorized Signatory:
__________________________________________
Address
for Notice of Purchaser:
Address
for Delivery of Securities (Warrants) for Purchaser (if not same as address for
notice):
Subscription
Amount: $_________________
Shares:
_________________
Warrant
Shares: __________________
Brokerage
Account Name and Account Number (for delivery of shares via DWAC):
___________________________________________
Name of
Brokerage Firm or Agent To Receive Shares
______________________
Account
Name
______________________
Account
No.
______________________
DTC
No.
FOR
IMMEDIATE RELEASE:
September
8, 2010
7:00 a.m.
ET
ENTREMED
SECURES $5.1 MILLION IN REGISTERED
DIRECT OFFERING AND ENTERS INTO AGREEMENT
FOR
RIGHTS TO LICENSE ENMD-2076 IN CHINA
Financing
Extends Cash Runway Through 2011 and Sets Stage for Expanding ENMD-2076 Clinical
Development Program
ROCKVILLE, MD
– September 8,
2010 – EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company
focused on the development of ENMD-2076, its proprietary Aurora A/angiogenic
kinase inhibitor for the treatment of cancer, today announced that on September
7, 2010 it entered into a securities purchase agreement with a group of
strategic investors for gross proceeds of approximately $5.1
million. The Company expects to complete the offering on or about
September 8, 2010. The financing will provide capital to fund
operations through 2011 and enable the Company to move forward with expansion of
development plans for ENMD-2076, which is currently in Phase 1 and Phase 2
clinical trials. The ongoing Phase 2 trial of ENMD-2076 in ovarian
cancer patients continues on track and the Company looks forward to the
presentation of data early in 2011.
The
investor group was led by Tak W. Mak, Ph.D., Director of The Campbell Family
Institute for Cancer Research, and includes scientific advisors to EntreMed as
well as experienced investors who have expertise both in oncology drug
development and in drug development in the China markets. Concurrent with the
execution of the securities purchase agreement, EntreMed entered into a rights
agreement with Selected Value Therapeutics I, LLC (SVT) pursuant to which SVT
has an option to exercise, on behalf of the investors, certain license,
development and commercialization rights for ENMD-2076 in China, enabling the
Company to leverage the experience and access that these investors have in this
growing market. If the option is exercised, EntreMed will be entitled
to receive development milestone payments and royalties on future product sales
within the geographic market. The option is exercisable at any time until
December 31, 2011.
“We
worked with Selected Value Therapeutics to develop an innovative financing
structure that accomplishes our financing goals with minimum dilution to our
current investors,” said Michael M. Tarnow, Executive Chairman of
EntreMed. “The financing extends our cash runway through
2011. We are on track to complete our current Phase 2 ovarian cancer
study and, based on the results from our Phase 1 studies, will move forward with
our plans for expansion into additional clinical trials in other
indications. We view both the investment in the Company and the
option to participate in the clinical development of the compound in China as a
vote of confidence in the potential of ENMD-2076.”
Dr. Tak
W. Mak, a scientific advisor to EntreMed and a co-founder of Miikana
Therapeutics, Inc. which was later acquired by EntreMed in 2006, added, “I have
been involved with ENMD-2076 since its discovery by Miikana. We look
forward to EntreMed’s further development of this compound and are encouraged by
its potential to improve the lives of cancer patients in the U.S. and
abroad.”
Terms
of the Transaction
An
aggregate of 1,886,662 shares of EntreMed’s common stock and warrants to
purchase an aggregate of 377,327 shares of its common stock will be issued
pursuant to the securities purchase agreement. The shares of common
stock and warrants were offered in units consisting of one share of common stock
and 0.20 warrants to purchase one share of common stock at a price of $2.70 per
unit to a group of accredited investors. The common stock purchase
price represents the consolidated closing bid price of EntreMed’s common stock
on September 7, 2010. The warrants have a term of three years and an
exercise price of $2.825.
Net
proceeds from the offering will be approximately $4.7 million after deducting
fees and estimated offering expenses payable by EntreMed. In
connection with the financing, the investor group was offered the right to
designate one director to EntreMed’s Board of Directors, and the director
nominee, if selected, will be identified by SVT and submitted to EntreMed for
approval and election to the Company’s Board of Directors.
The
securities described above are being offered through a prospectus supplement and
accompanying base prospectus pursuant to a registration statement, previously
filed and declared effective by the Securities and Exchange Commission
(SEC). The prospectus supplement related to the offering will be
filed with the SEC. Ferghana Partners acted as financial advisor to
EntreMed for these transactions. Copies of the final prospectus supplement
and accompanying base prospectus can be obtained from EntreMed or at the SEC’s
website at
www.sec.gov
.
This
press release does not and shall not constitute an offer to sell or the
solicitation of an offer to buy any of the securities, nor shall there be any
sale of the securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any state.
About
EntreMed
EntreMed,
Inc. is a clinical-stage pharmaceutical company committed to developing
ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of
cancer. ENMD-2076 is currently in a multi-center Phase 2 study in
ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma,
and leukemia. Additional information about EntreMed is available on
the Company’s web site at www.entremed.com and in various filings with the
Securities and Exchange Commission.
Forward
Looking Statements
This
release contains forward-looking statements within the meaning of the Private
Securities Litigation Reform Act with respect to the outlook for expectations
for future financial or business performance, strategies, expectations and
goals. Forward-looking statements are subject to numerous assumptions, risks and
uncertainties, which change over time. Forward-looking statements speak
only as of the date they are made, and no duty to update forward-looking
statements is assumed. Actual results could differ materially from those
currently anticipated due to a number of factors, including those set forth in
Securities and Exchange Commission filings under "Risk Factors," including
the risk that we may be unable to continue as a going concern as a result
of our inability to raise sufficient capital for our operational needs; the
possibility that we may be delisted from trading on the Nasdaq Capital Market;
the volatility of our common stock; risks relating to the need for additional
capital and the uncertainty of securing additional funding on favorable terms;
the failure to consummate a transaction to monetize the royalty stream for any
reason, including our inability to obtain the required third-party consents;
declines in actual sales of Thalomid
®
resulting in reduced revenues; risks associated with the Company’s
product candidates; the early-stage products under development; results in
preclinical models are not necessarily indicative of clinical results;
uncertainties relating to preclinical and clinical trials, including delays to
the commencement of such trials; success in the clinical development of any
products; dependence on third parties; future capital needs; and risks relating
to the commercialization, if any, of the Company's proposed products (such as
marketing, safety, regulatory, patent, product liability, supply, competition
and other risks).
Contact:
Ginny
Dunn
Associate
Director
Corporate
Communications & Investor Relations
240-864-2643
###